·9 min readFeatured
China Biotech Weekly #1: The ~$12B Signal — Why GSK-Hengrui Rewrites the Playbook
GSK-Hengrui's multi-asset deal valued at ~$12B reveals a new template for China out-licensing. Plus: 10 months to the BCC list, what CDE accepted this month, and the WuXi supply chain exposure that 34 US biotechs disclosed to the SEC.
GSKHengruiADCBIOSECUREdeal-analysis